Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Aaron E. Katz, MD, FACS, professor, Department of Urology, NYU Long Island School of Medicine, chairman, Department of Urology, Winthrop Hospital, NYU Langone Health’s Perlmutter Cancer Center, discusses redefining risk stratification for men with prostate cancer.

Historically, risk stratification for men with prostate cancer has been based on patients’ Gleason grading system score, prostate specific antigen level, number of cores, and rectal examination, says Katz. 

However, the field is moving toward an era of molecular stratification, Katz explains. This strategy could expand to other ​solid tumor types, such as breast cancer, ovarian cancer, and colon cancer, as well as hematologic malignancies ​like leukemia and lymphoma, Katz concludes.